NCT00390182View on ClinicalTrials.gov

Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Gastrointestinal NeoplasmsOvarian Neoplasms
Interventions
DRUG

Gemcitabine

"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.~\*\*Radiation is the experimental part of the study."

Trial Locations (2)

21201

University of Maryland & Baltimore VA medical centre, Baltimore

L8V 5C2

Juravinski Cancer Centre, Hamilton

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Maryland, Baltimore

OTHER

NCT00390182 - Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC) | Biotech Hunter | Biotech Hunter